Real-World Comparative Study of Ultra-Low-Dose Rivaroxaban in Very Elderly Patients with Atrial Fibrillation
In very elderly AF patients, ultra-low-dose rivaroxaban (5 mg daily) provided comparable efficacy to higher doses while significantly reducing major bleeding. This regimen may be a balanced option for high-risk elderly populations.
Authors
- Huanyu Ni (ORCID: https://orcid.org/0000-0002-6112-7799)
- Qian Ni
- Dan Han (ORCID: https://orcid.org/0000-0003-2183-2503)
- Baoyan Wang (ORCID: https://orcid.org/0000-0003-2661-2382)
- Jialin Qi (ORCID: https://orcid.org/0009-0003-7025-7311)
Institutions
- Nanjing Drum Tower Hospital (CN)
Publication Details
- Journal
- Clinical Interventions in Aging
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/cia.s555943
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Nanjing University
- Nanjing Drum Tower Hospital